FDA turmoil: Makary resignation and succession
FDA leadership shake-up raises continuity concerns
The U.S. Food and Drug Administration (FDA) has faced a rapid chain of leadership departures affecting both drug regulation and top executive oversight.
Multiple reports in the coverage describe how Dr. Marty Makary—FDA commissioner—resigned after weeks of turmoil, with experts warning that the shake-up could leave a leadership vacuum. In the described scenario, Makary’s departure occurred shortly after other senior changes, intensifying scrutiny of how quickly the agency can stabilize decision-making.
Alongside Makary’s exit, Dr. Tracy Beth Høeg, described as the FDA’s top drug regulator, also left her role as acting director of the FDA center overseeing prescription and over-the-counter drugs. In one account, Høeg said she was fired after declining to resign, while another report frames her departure as part of continuing upheaval just days after the FDA chief resigns.
A named successor for the commissioner role is described in the coverage: Kyle Diamantas, previously a top food official at the FDA, is set to serve as acting commissioner.
Why this matters for public health is that FDA leadership influences how swiftly and consistently the agency can:
- oversee drug and medical product regulation,
- manage approvals and post-market safety issues,
- provide policy clarity to industry and clinicians,
- and coordinate enforcement and regulatory priorities.
When leadership changes cluster close together, agencies can experience delays in internal processes and uncertainty about direction. While acting officials can maintain operations, the coverage highlights expert concern about whether the FDA’s regulatory pipeline and public-facing guidance will remain stable during the transition.
Overall, the reporting portrays a fast-moving leadership period in which the FDA must quickly reestablish continuity and accountability at multiple levels.